Skip to content

Sleep in Patients With Cystic Fibrosis

Predictors of Nocturnal Hypoventilation in Patients With Cystic Fibrosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00804661
Acronym
Sommeil
Enrollment
76
Registered
2008-12-09
Start date
2007-07-31
Completion date
2009-06-30
Last updated
2010-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Keywords

sleep, nocturnal hypoventilation, sleep quality, lung function

Brief summary

The aim of the study is to identify the parameters that are associated with nocturnal hypoventilation in children and adults with cystic fibrosis. Included patients will undergo a nocturnal evaluation of their gas exchange and sleep quality by actigraphy during their annual check up. The aim is thus to identify which parameters (such as lung function parameters) are associated with nocturnal hypercapnia or hypoxemia and/or poor sleep quality

Detailed description

Background In patients with cystic fibrosis (CF), respiratory disease is characterised by a progressive and ineluctable decline in lung function. Sleep-disordered breathing may occur at an early stage of lung disease and may impair quality of life. Oxygen therapy or noninvasive positive pressure ventilation may improve nocturnal hypoxemia and hypercapnia.Risk factors for nocturnal hypercapnia or hypoxemia are not well identified in patients with CF. Type of study : prospective, transversal, open Methods : During the annual check up, a sleep study will be performed with a nocturnal recording of a least 6 hours of pulse oximetry (SaO2) and transcutaneous carbon dioxide (PtcCO2) by the SENTEC device and wrist movements by means of actigraphy. The results of the sleep study will be correlated to· * clinical scores which evaluate sleep quality (such as the PITTSBURG Sleep Quality Score).· * respiratory function parameters : lung volumes, forced expiratory of the respiratory muscles: maximal inspiratory and expiratory pressures and the sniff nasal inspiratory pressure.· * nutritional state with the body mass index z-score· * the presence of arterial pulmonary hypertension on an echocardiography· * infectious status (colonisation by Staphylococcus aureus or Pseudomonas aeruginosa) and the CFTR genotype. Expected results This study should be able to document abnormal nocturnal gas exchange and sleep-disordered breathing in patients with CF in a stable state. The identification of parameters associated with nocturnal hypoventilation and/or poor sleep quality will help to screen those patients who will need a sleep study and treatment such as oxygen therapy or noninvasive positive pressure ventilation.

Interventions

DEVICESENTEC device

Nocturnal recording SAO2 and PtcCO2 and wrist movements by means of actigraphy

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
8 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* children \> 8 years and adults with CF * in a stable state (no acute respiratory exacerbation since one month or patient finishing an antibiotic course) * able to perform reproducible forced expiratory flows * having a forced expiratory volume in one second ≤ 60% predicted value * who accepts to perform a sleep study in the hospital during one night * written agreement to participate to the study

Exclusion criteria

* acute respiratory exacerbation in the previous month or patient who has not finished an antibiotic course * Inability or impossibility to perform reproducible forced expiratory flows (pneumothorax during the previous year and/or without surgery) * having a forced expiratory volume in one second \> 60% predicted value * refusal or impossibility to perform a sleep study in the hospital during one night * patients receiving long term oxygen therapy or noninvasive positive pressure ventilation * no social security * impossibility of a medical examination

Design outcomes

Primary

MeasureTime frame
To determine clinical and functional parameters associated with nocturnal hypoventilation defined by· - A mean transcutaneous carbon dioxide pressure (PtcCO2) ≥ 45 mm Hg· - And/or a maximal PtcCO2 ≥ 55 mm Hg· - And/or a PtcCO2 ≥ 45 mm Hg during ≥ 50%At the inclusion visit

Secondary

MeasureTime frame
To determine clinical and functional parameters associated with- sleep -disordered breathing defined by the presence of arousals on actigraphy (Actiwatch™) in children and adults with CF - nocturnal hypoxemia defined by -- a mean pulse oximetry (SaO2)At the inclusion visit

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026